Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Fast Is The Blood Cancer Drugs Market Expected to Grow Between 2025 And 2029?

In recent times, the market size of drugs for blood cancer has seen substantial growth. The market, which stands at $74.78 billion in 2024, is expected to expand to $80.79 billion in 2025, marking a compound annual growth rate (CAGR) of 8.0%. Factors contributing to such growth during the historic period include progress in research and development, a rise in the aging population, enhanced awareness coupled with early diagnosis, and regulatory approvals.

What Growth Rate Is Anticipated for the Blood Cancer Drugs Market in the Coming Years?

Predictions indicate a robust expansion for the blood cancer drugs market in the forthcoming years. It’s projected to attain a size of $106.8 billion by 2029, expanding at a compound annual growth rate (CAGR) of 7.2%. The augmentation in the specified projection period can be associated with a rise in disease incidence, emerging markets, and beneficial care. Prominent trends for the projection period encapsulate investments in research and development, combination therapies, the detection of biomarkers, advancements in immunotherapy, and personalized medicine.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=2587&type=smp

Who Are the Leading Companies in the Blood Cancer Drugs Market?

Major companies operating in the blood cancer drugs market include Amgen Inc., AstraZeneca PLC, Bayer AG, Eli Lilly and Company Inc., Johnson & Johnson, Novartis AG, Pfizer Inc., AbbVie Inc., Takeda Pharmaceutical Company Limited, F. Hoffmann-La Roche Ltd., Bristol-Myers Squibb Company, Astellas Pharma Inc., Roche Holding AG, Merck & Co. Inc., Gilead Sciences Inc., Sanofi S.A., Eisai Co. Ltd., Jazz Pharmaceuticals plc, Kyowa Kirin Co. Ltd., Menarini Group, Millennium Pharmaceuticals Inc., Mundipharma International Limited, Mylan N.V., Ono Pharmaceutical Co. Ltd., Otsuka Pharmaceutical Co. Ltd., Pharmacyclics LLC, Regeneron Pharmaceuticals Inc., Seattle Genetics Inc., Servier Laboratories, Shire plc, Spectrum Pharmaceuticals Inc., Taiho Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., Tolero Pharmaceuticals Inc., UCB S.A., Vertex Pharmaceuticals Incorporated

What Are the Key Drivers of the Blood Cancer Drugs Market?

The rising death rates and the escalating number of incidents of blood cancer worldwide are key catalysts propelling the blood cancer drugs market forward. Various kinds of blood cancers encompass leukemia, lymphoma, myeloma, among others, each having distinct risk factors. Some can be managed or avoided through drug therapies, while others can lead to fatality. For instance, Bristol-Myers Squibb Company’s November 2022 report predicted about 1.85 million fresh cases of blood cancer around the globe in 2040. The breakdown includes 918,872 lymphoma cases, 656,345 leukemia cases, and 275,047 myeloma cases. The report further estimated approximately 1,100,000 deaths as a consequence of blood cancer in 2040. The surge in deaths and incidence of blood cancer cases globally fuels the growth of the blood cancer drug market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=2587&type=smp

What Are the Key Market Segments in the Blood Cancer Drugs Industry?

The blood cancer drugs market covered in this report is segmented –

1) By Blood Cancer Type: Leukemia, Lymphoma

2) By Drugs: Rituxan Or Mabthera (Rituximab), Gleevec Or Glivec (Imatinib), Revlimid (Lenalidomide), Velcade (Bortezomib), Tasigna (Nilotinib), Pomalyst (Pomalidomide), Vidaza (Azacitidine), Kyprolis (Carfilzomib), Adcetris (Brentuximab Vedotin), Other Drugs

3) By Treatment Approaches: Key Findings, Chemotherapeutic, MAbs/Targeted Therapies, Immunotherapeutic

Subsegments:

1) By Leukemia: Acute Lymphoblastic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML), Chronic Myeloid Leukemia (CML), Other Types of Leukemia

2) By Lymphoma: Hodgkin Lymphoma, Non-Hodgkin Lymphoma (NHL), Burkitt Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Other Types of Lymphoma

What Are the Latest Trends in the Blood Cancer Drugs Market?

Top firms in the blood cancer drugs market are strategically innovating new drugs and actively seeking FDA clearance to secure a competitive foothold. FDA approval outlines the official permission that the United States Food and Drug Administration (FDA) gives for a pharmaceutical product to be legally sold in the United States. To illustrate, Bristol Myers Squibb, a pharmaceutical company based in the US, gained FDA clearance in March 2024 for its unique CAR T-cell therapy. The therapy targets adults suffering from recurrent or treatment-resistant chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The approval greenlights its use in patients who have undergone at least two previous treatments, including Bruton tyrosine kinase inhibitor and a B-cell lymphoma 2 inhibitor. From the TRANSCEND CLL 004 trial, Breyanzi demonstrated a response rate of a complete 20% and a median length of response of approximately 35.3 months.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/blood-cancer-drugs-global-market-report

What Are the Key Regional Markets in the Blood Cancer Drugs Industry?

North America was the largest region in the blood cancer drugs market in 2023. Middle East is expected to be the fastest-growing region in the blood cancer drugs market during the forecast period. The regions covered in the blood cancer drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=2587

This Report Delivers Insight On:

1. How big is the blood cancer drugs market, and how is it changing globally?

2. Who are the major companies in the blood cancer drugs market, and how are they performing?

3. What are the key opportunities and risks in the blood cancer drugs market right now?

4. Which products or customer segments are growing the most in the blood cancer drugs market?

5. What factors are helping or slowing down the growth of the blood cancer drugs market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model